Cd30 clone berh2

Manufactured by Agilent Technologies

Sourced in Denmark, Germany

The CD30 (clone BerH2) is a laboratory reagent used for the detection and identification of CD30-positive cells. It is a monoclonal antibody that binds specifically to the CD30 antigen, which is expressed on the surface of certain types of cells, such as activated lymphocytes and some types of cancer cells. The CD30 (clone BerH2) can be used in various analytical techniques, such as flow cytometry and immunohistochemistry, to study the presence and distribution of CD30-positive cells in biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Cd20 clone l26, by Agilent Technologies (4 mentions) Bcl2 clone 124, by Agilent Technologies (2 mentions) Cd68 clone pg m1, by Agilent Technologies (1 mentions) Hamamatsu nanozoomer, by Hamamatsu Photonics (1 mentions) Bond max stainer, by Leica (1 mentions) Tissuestudio 64, by Definiens (1 mentions) Pd l1 clone e1l3n, by Cell Signaling Technology (1 mentions) Benchmark ultra stainer, by Roche (1 mentions) Pdgfra, by Thermo Fisher Scientific (1 mentions) Her2 clone 4b5, by Roche (1 mentions) Estrogen receptor clone sp1, by Roche (1 mentions) Alk clone 1a4, by Zytomed Systems (1 mentions) Egfr clone 3c6, by Roche (1 mentions) Her3 clone sp71, by Abcam (1 mentions) Phospho mtor clone 49f9, by Cell Signaling Technology (1 mentions) Pdgfrb clone 28e1, by Cell Signaling Technology (1 mentions) Progesterone receptor clone 1e2, by Roche (1 mentions) Pten clone y184, by Abcam (1 mentions) Ros1 clone d4d6, by Cell Signaling Technology (1 mentions) Met clone sp44, by Roche (1 mentions)

7 protocols using cd30 clone berh2

Quantitative Lymph Node Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

For each patient, the whole available tissue specimen/block was cut and subsequent slides were stained in the Department of Pathology at Kiel University for CD3 (clone SP7, Waltham, MA, USA), CD20 (clone L26, Dako, Glostrup, Denmark), CD30 (clone BerH2, maintained at the Department of Pathology, Kiel, Germany) and CD68 (clone PG-M1, Dako, Glostrup, Denmark), using a Leica-Bond-Max stainer (Leica Microsystems, Wetzlar, Germany). The slides were scanned (Hamamatsu Nanozoomer, Hamamatsu Photonics, Ammersee, Germany) and the resulting images were processed by TissueStudio 64, according to the manufacturer’s recommendations (Definiens AG, Munich, Germany). The area ranged between 4-455 mm^{2 (link)} (mean: 133.81 mm^{2 (link)}, standard deviation [SD]: 80.84 mm^{2 (link)}) (Online Supplementary Figure S1). Since we included the entire lymph node in the analysis, any heterogeneity of cell distribution did not influence our data. Cutting artifacts, and overstained or unstained areas were manually excluded from the analysis. Adjusting the threshold based on several representative locations on the sample also ensured that the setting for analysis for each sample had been selected to cover the specific staining of the lymph node. See the Online Supplementary Methods for a detailed description and statistics.

Jachimowicz R.D., Pieper L., Reinke S., Gontarewicz A., Plütschow A., Haverkamp H., Frauenfeld L., Fend F., Overkamp M., Jochims F., Thorns C., Leo Hansmann M., Möller P., Rosenwald A., Stein H., Reinhardt H.C., Borchmann P., von Tresckow B., Engert A, & Klapper W. (2020). Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica, 106(6), 1684-1692.

+ Open protocol

+ Expand

Comprehensive IHC Antibody Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was performed with a Ventana Benchmark Ultra stainer (Ventana, Tucson, AZ, USA). The following antibodies were employed: ALK (clone 1A4; Zytomed, Berlin, Germany), CD30 (clone BerH2; Dako, Vienna, Austria), CD20 (clone L26; Dako), EGFR (clone 3C6; Ventana), Estrogen-receptor (clone SP1; Ventana), HER2 (clone 4B5; Ventana), HER3 (clone SP71; Abcam), KIT (clone 9.7; Ventana), MET (clone SP44; Ventana), phospho-mTOR (clone 49F9; Cell Signalling Technology Inc., Danvers, MA, USA), PDGFRA (rabbit polyclonal; Thermo Fisher Scientific), PDGFRB (clone 28E1, Cell Signalling), PD-L1 (clone E1L3N; Cell Signalling), Progesterone-receptor (clone 1E2; Ventana), PTEN (clone Y184; Abcam) and ROS1 (clone D4D6; Cell Signalling).

Unseld M., Mader R., Baumann L., Veraar C., Wrba F., Waneck F., Kieler M., Bianconi D., Berger W., Sibilia M., Müllauer L., Zielinski C, & Prager G.W. (2018). Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT. Chinese Journal of Cancer Research, 30(5), 508-515.

+ Open protocol

+ Expand

Immunocytochemical Analysis of Malignant Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunocytochemical analysis was possible only on CBs, on three micron-thick unstained sections. An initial panel of antibodies was used in malignant cases to differentiate lymphoma from carcinoma and sarcoma, namely pan-cytokeratin (clone AE1/3; DAKO, Carpinteria, CA, USA), CD45/LCA (Clones 2B11+PD7/26; DAKO), CD20 (clone L26; DAKO), CD79α (clone JCB 117; DAKO), CD3 (polyclonal; DAKO), EMA (clone E29; DAKO), CD30 (clone Ber-H2; DAKO), CD15 (clone Carb-3; DAKO) and PAX5 (clone DAK-PAX5; DAKO). In case a diagnosis of B-lineage NHL had been advanced, a second lineage of immunocytochemical markers was performed, including BCL2 (clone 124; DAKO), BCL6 (clone PG-B6p; DAKO), CD10 (clone 56C6; DAKO), CD5 (clone 4C7; DAKO), CyclinD1 (clone EP12; DAKO), MUM1/IRF4 (clone MUM1p; DAKO) and Mib1 (clone Ki67; DAKO). All staining procedures were carried out on Autostainer Link48 (DAKO, DAKO), according to the manufacturer’s instructions and in the presence of appropriate controls. Neither morphology nor first- nor second-line immunocytochemical analyses aroused suspicion of T-lineage NHL.

Parente P., Covelli C., Zanelli M., Trombetta D., Carosi I., Carbonelli C., Sperandeo M., Mastracci L., Biancofiore G., Zizzo M., Taurchini M., Ascani S, & Graziano P. (2020). Diagnosis of Hodgkin Lymphoma from Cell Block: A Reliable and Helpful Tool in “Selected” Diagnostic Practice. Diagnostics, 10(10), 748.

+ Open protocol

+ Expand

Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tissue microarrays prepared from the diagnostic formalin-fixed, paraffin-embedded (FFPE) tissue blocks of all patients studied were stained with an anti-p63 antibody (4A4, Santa Cruz Biotechnology, Santa Cruz, CA) which can detect all p63 isoforms. Expression levels of p63 were determined by estimating the percentage of p63-positive tumor cells in the tissue array cores. X-tile software and receiver operating characteristic curve analysis by GraphPad Prism 6 Software were used to determine the percentage of p63-positive cells with maximal discriminatory power for the separation of DLBCL patients into 2 different prognostic groups. Evaluation of other biomarkers by immunohistochemistry was also performed on tissue microarrays using corresponding antibodies: p53 (DO-7, Dako, Carpinteria, CA), MDM2 (IF2, Calbiochem, Billerica, MA), p21 (Dako), Bcl-2 (Clone-124, Dako, Carpinteria, CA), Ki-67 (Dako), CD30 (clone BerH2, Dako), Bcl-6 (Dako), FOXP1 (Abcam), IRF4/MUM1 (Dako), CD10 (56C6, Vantana), c-Rel (Dako), and CXCR4 (Abcam, San Francisco, CA). Details of immunohistochemistry procedures and scoring processes have been described previously [38 (link), 44 (link), 55 (link)–58 (link)].

Xu-Monette Z.Y., Zhang S., Li X., Manyam G.C., Wang X.X., Xia Y., Visco C., Tzankov A., Zhang L., Montes-Moreno S., Dybkaer K., Chiu A., Orazi A., Zu Y., Bhagat G., Richards K.L., Hsi E.D., Choi W.W., van Krieken J.H., Huh J., Ponzoni M., Ferreri A.J., Zhao X., Møller M.B., Parsons B.M., Winter J.N., Piris M.A., Medeiros L.J, & Young K.H. (2016). p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY), 8(2), 345-365.

+ Open protocol

+ Expand

Comprehensive Immunohistochemistry Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry on cell block and FFPE capsular specimens was performed using an automated immunostainer (Dako, Glostrup, Denmark) with the following primary antibodies: CD30 (clone Ber-H2), CD3 (clone F7.2.38), CD4 (clone 4B12), CD8 (clone C8/144B), CD68 (clone PG1), CD15 (clone Car-b), Granzyme B (clone GrB-7), IRF-4 (clone MUM1) (Dako), CD25 (clone 4C9, Novocastra, Newcastle Upon Tyne, UK), PAX5 (clone SP34, Thermo Scientific, Waltham, USA). Paraffin sections were pretreated using EnVision^™ FLEX Target Retrieval Solution (Dako) and incubated with an optimal dilution of the primary antibody. The reaction was visualized with the EnVision Detection Kit (Dako) using 3–3’-diaminobenzidine chromogenic substrate. Sections were counterstained with EnVision FLEX Hematoxylin (Link) (Dako).
For every marker, positive cells were counted out of 10 non-overlapping randomly selected high-power microscopic fields (HPFs, 40×10), and the mean number of positively stained cells per HPF was recorded. The percentage of positive cells was calculated as the ratio between the mean number of stained cells per HPF and the mean number of total cells per HPF.

Di Napoli A., Pepe G., Giarnieri E., Cippitelli C., Bonifacino A., Mattei M., Martelli M., Falasca C., Cox M.C., Santino I, & Giovagnoli M.R. (2017). Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma. PLoS ONE, 12(7), e0181097.

+ Open protocol

+ Expand

In Situ Cytokine Expression in Seromas

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cytokine mRNA production of IL6 and IL10 was further investigated by RNA in situ hybridization (ISH) using RNAscope technology. The RNAscope assay was applied to cell block paraffin sections of late seromas as previously described [16 (link), 17 (link)]. Briefly, FFPE Sects. 2 μm thick were deparaffinized in xylene and then hydrated in an ethanol series. Hybridization was with target probes: Probe-Hs-IL6 and Probe-Hs-IL10. The preamplifier, amplifier, label probe, and chromogenic detection procedures were performed according to the manufacturer’s instructions (RNAscope® 2.0 HD Reagent Kit, Advanced Cell Diagnostics, Newark CA, USA).
For double staining, RNAscope assay for IL6 and IL10 was performed first and followed by immunohistochemistry for CD30 (clone Ber-H2, diluition 1:50) (Dako, Denmark). Staining was revealed using Super Sensitive Link Label IHC Detection System Alkaline Phosphatase (BioGenex, Fremont, CA, USA). Vulcan Fast Red Chromogen Kit 2 (BioCare Medical, Pacheco, CA, USA) was used as substrate-chromogens, followed by counterstaining with Harris hematoxylin.

Di Napoli A., Greco D., Scafetta G., Ascenzi F., Gulino A., Aurisicchio L., Santanelli Di Pompeo F., Bonifacino A., Giarnieri E., Morgan J., Mancini R, & Kadin M.E. (2020). IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas. Cancer Immunology, Immunotherapy, 70(5), 1379-1392.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Hematologic Malignancies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Formalin-fixed paraffin-embedded tissues were stained with hematoxylin and eosin at the initial diagnosis. Immunohistochemistry was performed using the following panel of monoclonal and polyclonal antibodies: CD20 (clone L26, DAKO, Glostrup, Denmark); CD79a (clone 1.10E + 04, Leica Biosystems, Wetzlar, Germany); PAX5 (clone R1, DAKO); CD10 (clone 56C6, Leica Biosystems); BCL6 (clone P1F6, DAKO); MUM1 (clone MUM1p, DAKO); Ki-67 (clone MIB-1, DAKO); Terminal deoxynucleotidyl transferase (TDT, clone SP150, DAKO); CD2 (clone AB75, DAKO); CD3 (clone LN10, Leica Biosystems); CD4 (clone SP35, DAKO); CD7 (DAKO); CD8 (clone SP16, DAKO); CD1a (clone SP157, DAKO); CD34 (clone QBEnd/10, DAKO); CD43 (clone DF-T1, DAKO); CD99 (clone HO36-1.1, DAKO); CD117 (clone C-KIT, DAKO); CD45 (clone PAN-LCAL, DAKO); CD33 (clone WM-54, DAKO); MPO (clone SP72, DAKO); CD15 (clone C3D-1, DAKO); CD30 (clone Ber-H2, DAKO); CD23 (clone SP23, DAKO); and Epithelial membrane antigen (EMA, clone GP1.4, Leica Biosystems).

Chen L., Wang M., Fan H., Hu F, & Liu T. (2017). Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features. Scientific Reports, 7, 2577.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!